2 drug giants are feuding over a highly successful new migraine drug, and court documents reveal how profitable the $10 billion market could be

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 51%

United States News News

United States United States Latest News,United States United States Headlines

Two drugmakers, Amgen and Novartis, have worked together for years on a new type of cutting-edge migraine drug, Aimovig.

The origins of their quarrel also started that year, when a unit of Novartis called Sandoz began working with another migraine company, the biotech Alder Biopharmaceuticals. Sandoz was manufacturing the experimental migraine drug ALD403 at a factory in Austria.

Amgen objected, and the two companies have been going back and forth about it since then. On Tuesday, Amgen gave Novartis notice that it wanted to terminate their collaboration.product to Aimovig and other, already-approved drugs from generic drugmaker Teva and pharma Eli Lilly. They all use a similar scientific approach to treating migraines preventatively, or before they happen.

The Swiss drug giant also says it's invested too much in Aimovig to get cut out now, having spent about $530 million to help out with the US launch last May. And though the companies haven't really disclosed how that breaks down, most assume they're roughly splitting profits, Mizuho analyst Salim Syed said.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

We have to work on a surgical fix for migranes. This is scar tissue from a tramatic injury causing blockage. A structural weakness in the vascular system. Maybe a stint fix. Patch it.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in US

United States United States Latest News, United States United States Headlines